Advocates: HIV prevention pill could save lives
In this Thursday, May 10, 2012 photo, Dr. Lisa Sterman holds up a Truvada pill at her office in San Francisco. Sterman prescribes the drug off-label for about a dozen patients at high risk for developing AIDS. The pill, already used to treat people with HIV, also helps prevent the virus from infecting healthy people. The Food and Drug Administration is expected to decide by June 15 whether the pill’s maker Gilead Sciences should be allowed to formally market the drug for preventive use. (AP Photo/Jeff Chiu)
(AP) -- A pill to prevent HIV infection is already being given to some healthy people, but without government approval, it remains out of reach and too costly for many who need it.
Doctors, patients and advocates say that would change if the Food and Drug Administration takes a landmark step and allows the pill, Truvada, to be marketed for prevention. The drug has been used for some time as a treatment for those already infected with the AIDS virus.
"This is a pretty radical step, but I think it's a necessary step," said Dr. Lisa Sterman of San Francisco, who prescribes the drug for already infected patients and those who are healthy but at risk of getting the virus from their partners or through risky sex.
A panel of advisers to the Food and Drug Administration late Thursday endorsed using Truvada as a preventive.
In the 30-year battle against AIDS, "it's the first time we have talked about a medication for prevention of HIV," Sterman said.
Doctors are allowed to prescribe Truvada "off-label" for prevention, but FDA approval would formally allow the pill's maker Gilead Sciences to market it for that use. It likely would lead many more insurance companies to pay for the costly drug. The FDA usually follows advisers' recommendations and a decision is expected by June 15.
The panel's action "is a huge step forward," said Nick Literski, a federal worker in Seattle who has been taking Truvada for HIV prevention for more than a year. His partner has the AIDS virus. Literski's insurance covers his preventive treatment. The pill's annual cost ranges from just under $11,000 up to $14,000.
Using the drug for prevention "is really allowing people to make educated choices about their health," Literski said.
An estimated 1.2 million Americans have HIV and many more worldwide. AIDS can develop unless the virus is treated with antiviral drugs. The success of such medicines has helped make the disease more manageable and allows patients to live much longer than when the epidemic began 30 years ago.
About 50,000 new HIV infections are diagnosed in the U.S. each year - a number that has held steady for about 15 years.
"We're going to have to take some radical steps in order to stop this epidemic," Sterman said.
Truvada is marketed by Gilead Sciences Inc. of Foster City, Calif. Studies have shown daily use is highly effective at preventing HIV infections.
James Loduca, a spokesman for the San Francisco AIDS Foundation, praised the advisory panel's action.
"With this recommendation, we're nearing a watershed moment in our fight against HIV," Loduca said. "We know this isn't a magic bullet, and it's not going to be the right prevention strategy for everyone, but it could save thousands of lives in the United States and potentially millions around the world."
Not everyone in the HIV community is so gung-ho about using Truvada for prevention.
Michael Weinstein, president of AIDS Healthcare Foundation, is among the most vocal opponents. His Los Angeles-based group bills itself as the nation's largest provider of medical care for HIV and AIDS, and Weinstein's main concern is that patients won't take the drug as directed - a pill a day plus the use of condoms. Misuse could create drug-resistant HIV strains, and lead to more infections.
The FDA panelists acknowledged that concern, and said people should be tested to make sure they don't have HIV before starting Truvada. Patients who already have the virus and begin taking Truvada could develop a resistance to the drug, making their disease even more difficult to treat.
Justin Terry-Smith, a Washington, D.C.-area writer with HIV, has different concerns. He took Truvada for four years to suppress his infection. He said he has friends with the AIDS virus in other cities who can't find the drug, and he worries that making it widely available for prevention could result in shortages and pose problems for patients who need it for treatment.
"There has to much more production of this drug for this to actually go forward," he said.
His doctor recently put him on another drug regimen - switching medicines is a common tactic in HIV treatment. But unlike his other HIV medicines, Truvada had no side effects, and he said it needs to remain available for already infected patients.
Sterman said approval of Truvada for prevention would be unlikely to lead to shortages because the drug would only be recommended for people at high risk for getting the virus.
"I don't think demand for it is going to be that high," she said.
Truvada's costs are another concern. But supporters of the drug note that the lifetime cost of treating one person diagnosed with the AIDS virus has been estimated at more than $600,000.
"It's much more cost-effective to prevent a new infection than it is to treat someone for their lifetime," Loduca said. "Of course the ultimate goal is a vaccine and a cure but we're many years away from that."
Jim Pickett, director of prevention advocacy and gay men's health at the AIDS Foundation of Chicago, has had the AIDS virus since 1995. He says his medical costs, including medicine and doctor visits, have continually increased since then and now total about $20,000 a year, mostly covered by his health insurance.
He took Truvada for a while for HIV treatment and had no complications. Side effects from long-term use are uncertain, but some of the more serious complications linked with Truvada include kidney and liver problems.
For some people, the risk for kidney problems "10 years down the line may be less than the risk for acquiring HIV, which is significantly more problematic and can be fatal," Pickett said.
"We need options for people. This is one option. It wouldn't be an option for everybody. It's not meant for everybody," Pickett said.
More information: FDA: http://www.fda.gov
©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- FDA review favors first drug for HIV prevention (Update) May 08, 2012 | not rated yet | 0
- FDA panel backs first pill to block HIV infection May 11, 2012 | not rated yet | 0
- AIDS prevention pill study halted; no benefit seen Apr 18, 2011 | not rated yet | 0
- US health advisors mull AIDS prevention pill (Update) May 10, 2012 | not rated yet | 0
- Anti-AIDS groups hail drug but worry over cost Nov 24, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...
HIV & AIDS 12 hours ago | not rated yet | 0
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
HIV & AIDS May 19, 2013 | 5 / 5 (1) | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
HIV & AIDS May 18, 2013 | 5 / 5 (2) | 0
Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...
HIV & AIDS May 17, 2013 | not rated yet | 0
(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.
HIV & AIDS May 17, 2013 | not rated yet | 0
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
56 minutes ago | not rated yet | 0 |
(HealthDay)—The overall health of Americans isn't improving much, with about six in 10 people either overweight or obese and large numbers engaging in unhealthy behaviors like smoking, heavy drinking or ...
1 hour ago | not rated yet | 0
(HealthDay)—In 2008 to 2010, the prevalence of key health behaviors among U.S. adults varied, with about one in five adults current smokers and 62.1 percent overweight or obese, according to a report presented ...
56 minutes ago | not rated yet | 0
(HealthDay)—Factors such as increased case finding may explain why Michigan had half of the total spinal infections associated with contaminated methylprednisolone acetate in the recent fungal meningitis ...
46 minutes ago | not rated yet | 0
Early use of tracheostomy for mechanically ventilated patients not associated with improved survival
For critically ill patients receiving mechanical ventilation, early tracheostomy (within the first 4 days after admission) was not associated with an improvement in the risk of death within 30 days compared to patients who ...
56 minutes ago | not rated yet | 0
(HealthDay)—Three-quarters of public schools in the metro Atlanta area contain microbes, including bacteria indicating the presence of fecal matter, according to research published in the May 17 issue of ...
36 minutes ago | not rated yet | 0